ASSeSSing the risk of fatal cardiovascular disease

Similar documents
Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

CVD Prevention, Who to Consider

2016 EUROPEAN GUIDELINES ON CVD PREVENTION IN CLINICAL PRACTICE

Risk Factors for Heart Disease

Depok-Indonesia STEPS Survey 2003

Dietary recommendations in Obesity, Hypertension, Hyperlipidemia, and Diabetes. Stephen D. Sisson MD

Part 1: Obesity. Dietary recommendations in Obesity, Hypertension, Hyperlipidemia, and Diabetes 10/15/2018. Objectives.

Chapter 18. Diet and Health

2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.

Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION

Cardiovascular disease - from management to prevention

2013 Hypertension Measure Group Patient Visit Form

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

Diabetes Mellitus: A Cardiovascular Disease

Cardiovascular Risk Assessment and Management Making a Difference

Screening Results. Juniata College. Juniata College. Screening Results. October 11, October 12, 2016

New ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Lipids. Professor Željko Reiner, MD, PhD, FRCP(Lond), FESC, FACC

Notes Indicate to the group that this patient will be the focus of today s case discussion.

Type 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.

1. Which one of the following patients does not need to be screened for hyperlipidemia:

7/6/2012. University Pharmacy 5254 Anthony Wayne Drive Detroit, MI (313)

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Impact of Lifestyle Modification to Reduce Cardiovascular Disease Event Risk of High Risk Patients with Low Levels of HDL C

Using the New Hypertension Guidelines

Key Elements in Managing Diabetes

Conflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines

Guidelines on cardiovascular risk assessment and management

Prevenzione cardiovascolare e cambiamento degli stili di vita. Gian Franco Gensini

Prevention of MACROvascular Complications of Diabetes

SIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence

Identification of subjects at high risk for cardiovascular disease

Absolute cardiovascular disease risk management

STAYING HEART HEALTHY PAVAN PATEL, MD CONSULTANT CARDIOLOGIST FLORIDA HEART GROUP

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group

Total risk management of Cardiovascular diseases Nobuhiro Yamada

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic


Obesity Prevention and Control: Provider Education with Patient Intervention

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN

Report Operation Heart to Heart

Session 21: Heart Health

Heart Health. Team Member Workbook Session 1 LEARN IDENTIFY ACT. Learn about HTHU Level 3 and the point system

Dyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies

hypertension Head of prevention and control of CVD disease office Ministry of heath

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

American Diabetes Association: Standards of Medical Care in Diabetes 2015

Diabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Apelin and Visfatin Plasma Levels in Healthy Individuals With High Normal Blood Pressure

How to Reduce CVD Complications in Diabetes?

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Metabolic Syndrome and Chronic Kidney Disease

Diabetic Dyslipidemia

Personal Diabetes Passport

Cardiovascular Complications of Diabetes

overweight you are part of it!... Healthier, fitter, safer... Seafarers Health Information Programme ICSW S.H.I.P.

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology

Coronary Artery Disease Clinical Practice Guidelines

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu

Health First. New Health Bucks Program MANATEE YOURCHOICE HEALTH PLAN

What is hypertension?

Overweight. You are part of it! Healthier, fitter, safer.

What s New? Hypertension Canada Guidelines for the Management of Hypertension

Metabolic Syndrome: A Preventable & Treatable Cluster of Conditions

Table S1. Characteristics associated with frequency of nut consumption (full entire sample; Nn=4,416).

How Low Do We Go? Update on Hypertension

Metabolic Syndrome: Why Should We Look For It?

Metabolic Syndrome.

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up

Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology

!!! Aggregate Report Fasting Biometric Screening CLIENT!XXXX. May 2, ,000 participants

Heart Outcomes Prevention Evaluation (HOPE) - 3 Combined Lipid Lowering and Blood Pressure Lowering in Moderate Risk People

Diabetes and Heart Disease

CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES

Hypertension JNC 8 (2014)

Cardiovascular disease is the most prev -

DYSLIPIDEMIA RECOMMENDATIONS

Long-Term Complications of Diabetes Mellitus Macrovascular Complication

BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS

Andrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am

APPENDIX 2F Management of Cholesterol

Clinical Care Performance. Financial Year 2012 to 2018

Established Risk Factors for Coronary Heart Disease (CHD)

Case Study: Chris Arden. Peripheral Arterial Disease

Objectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015

Supplementary Table 1. Patient demographics and baseline characteristics (treated patients).

The Metabolic Syndrome

Clinical Practice Guideline

Patient is healthy with no chronic disease or significant risk factors [16%].

Elevation of Serum Creatinine: When to Screen, When to Refer. Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC

1/14/2013 Pediatric Cardiovascular Disease and the Future of our Children Linda Alwine FNP-BC Objectives Identify the prevalence and epidemiology of h

Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?

Health Score SM Member Guide

Reducing risk in heart disease

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?

Transcription:

ASSeSSing the risk of fatal cardiovascular disease «Systematic Cerebrovascular and coronary Risk Evaluation» think total vascular risk Assess the risk Set the targets Act to get to goal revised; aupril 25 th 2012 Multiple risk factors usually contribute to the atherosclerosis that causes cardiovascular disease. These risk factors interact, sometimes multiplicatively. Manment of the individual components of risk such as smoking, diet, exercise, blood pressure and lipids impacts on total cardiovascular risk. Thus the aim should be to reduce total risk; if a target cannot be reached with one risk factor, total risk can still be reduced by reducing other risk factors. Recommended by Canadian Vascular Coalition 2004

how 1 Find the cell nearest to the person s gender,, total/hdl-chol. ratio and systolic blood pressure values, bearing in mind that the risk will be higher as the person approaches the next, cholesterol or blood pressure category. 2 This will give you a percent representing the risk of dying from vascular disease in next 10 years. 3 Risk may be higher than indicated in the chart if: preclinical atherosclerosis already established; family history of premature cardiovascular disease: X 1.7 (men), X 2.0 (women); obesity, BMI > 30 Kg/m 2, waist circumference 102 cm or higher in men or 88 cm or higher in women; sedentarity; diabetes: multiply by 3 in men and by 5 in women; very high triglycerides; high levels of hsc-reactive protein, fibrinogen, homocystein, apoliprotein B or Lp(a). Interpretation (Risk level) <1 % 1 % 2 % 3 à 4 % 5 à 9 % 10 à 14% 15 % Low ( <1% ) High ( >5%) Use SCORE unless known cardiovascular disease, diabetes with microalbuminuria, markedly increased single risk factors or older than 70 years of. The charts should be used in the light of the clinician s knowledge and judgement, especially with regard to local conditions. relative risk chart Use this chart to show younger people, less than 40, at low total risk that, relative to their group, their risk may be many times higher than necessary. This may help to motivate decisions about avoidance of smoking, healty nutrition and exercise, as well as flagging those who may become candidates for medication. Systolic BP <40 6 7 8 10 12 Total cholesterol to HDL-C ratio

ASSeSSing 10 year risk of fatal cardiovascular disease Women Men 5 7 8 10 11 65 10 13 15 18 20 7 9 11 13 14 5 7 8 9 10 9 12 14 17 19 7 9 10 12 14 5 7 8 9 10 65 17 22 26 30 33 13 16 19 22 25 9 12 14 16 18 6 8 10 12 13 Systolic blood pressure (mmhg) 3 4 5 5 6 2 3 3 4 5 2 2 3 3 3 0 0 0 1 1 60 55 50 6 7 9 10 12 3 4 5 6 6 2 3 3 4 5 2 2 2 3 3 Systolic blood pressure (mmhg) 6 7 9 10 12 2 3 4 4 5 1 1 1 1 2 60 55 50 11 13 16 19 21 8 10 12 14 16 5 7 8 10 11 6 8 10 12 13 5 6 7 8 9 2 3 4 4 5 0 0 0 0 1 40 0 0 1 1 1 0 0 0 0 1 Total cholesterol to HDL -C ratio 0 0 1 1 1 40 Total cholesterol to HDL -C ratio determining vascular Vascular, or the of a person s arteries, is determined by comparing a person's risk with that of an older person having the same risk level but risk factor values situated in an optimal interval. More information can be found on the following website: www.score-canada.ca Vascular Age evaluation table After having used the SCORE chart to calculate the % of risk, use this table to estimate the vascular. SCORE 1 2 3 9 11 13 VA women 58 64 68 71 73 75 77 79 81 83 85 VA men 53 60 65 69 72 75 77 79 81 85 88

What are the objectives of vascular prevention? 1 To Assist those at low risk of vascular disease to maintain this state lifelong, and to help those at higher increased total vascular risk to reduce it. 2 To Obtain the caracteristics of people who tend to stay healthy: 0 No smoking 5 Five portions of fruit and vegetable or more a day and healthy food choices 30 Thirty minutes of physical exercise (moderate intensity) a day Blood pressure under /90 mmhg 5 Total-cholesterol under 5 mmol/l 3 LDL-cholesterol under 3 mmol/l 0 Zero diabetes ; fasting plasma glucose under 7 mmol/l 0 Zero obesity ; BMI under 25 Kg/m 2 and no abdominal obesity 3 To achieve more rigorous risk factor control in high risk subjects, especially those with established vascular disease, diabetes or kidney disease. Lifestyle Therapies in Hypertensive Adults Intervention Target Limit sodium-added food < 1500 mg/day Weight reduction BMI < 25 kg/m 2 Alcohol restriction < 2 drinks/day Physical activity 30-60 minutes 4-7 days/week Dietary patterns DASH diet Smoking cessation Smoke free environnement 2012 Canadian Hypertension Education Program Recommendations Vascular Risk and Target Lipid levels Risk Level Primary Targets LDL-C (mmol/l) Apo B (g/l) High < 2.0 ou 50% < 0.80 Moderate Clinical judgement Low Clinical judgement Æ LDL-C = LDL-Cholesterol; Apo B = Apolipoprotein B level Adapted from: Can J cardiol. 2009 Oct; 25(10): 567-579 Blood pressure target values for treatment of hypertension Condition Isolated systolic hypertension < Systolic Diastolic hypertension Systolic BP < Diastolic BP < 90 Diabetes Systolic BP < 130 Diastolic BP < 80 2012 Canadian Hypertension Education Program Recommendations 4 To prescribe ASA, statin, ACE-I or ARB in these high risk subjects, especially those with established atherosclerotic disease. 5 To consider pharmacological treatment to control hypertension and/or diabetes. Target SBP and DBP (mm Hg) Recommended targets for glycemic control A1C FPG PG (%) (8h)orpreprandial 2h postprandial (mmol/l) (mmol/l) Diabetes < 7.0 4.0-7.0 5.0-10.0 Type 1 and (5.0-8.0 if A1C targets Type 2 not being met) A1C = Glycated hemoglobin; FPG = Fasting plasma glucose; PG = plasma glucose Canadian Diabetes Association 2008 Clinical Practice Guidelines, S30 «Systematic Cerebrovascular and coronary Risk Evaluation» Assessing 10 year risk of fatal cardiovascular disease

Established vascular disease Diabetes Man > 45(years old) Women > 50(years old) Diabetes > 15 years and d > 30 CV Multi risk Microvascular disease Markedly elevated single risk factor E.g.: LDL-C > 6 mmol/l BP > /110, SCORE Risk > 5 % SCORE Risk < 5 % 0 No smoking recommendations 5 portions of fruit and vegetable or more a day and varied healthy foods, cereals or whole wheat bread, fish, limit salt (sodium) intake Lifestyle advice to maintain low risk status 30 minutes of moderately vigorous exercise on most days Reduce weight if BMI > 25 kg/m 2 or waist circumference equal or higher than 88 cm (women), 102 cm (men) 0 5 30 PREVENTION COMBINATION If SCORE risk is equal or exceeds 5 % or if there is established vascular disease or diabetes with end organ dam: Consider ASA, Statin, ACE-I or ARB Consider a pharmacological treatment to control hypertension and/or diabetes. SCORE Canada by René Gagnon M.D., Denis Drouin M.D. and Guy Tremblay M.D. www.score-canada.ca Re-assess total risk every two years Bruno Roy graphiste brgraph@sympatico.ca